Drug guidance
Botulinum toxin A for treating cervical dystonia
Condition
Musculoskeletal
16 September 2025
Published on 02 Sep 2019
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials, and
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 U and 500 U injection vials
for treating adults with cervical dystonia.
Botulinum toxin A must be administered by a neurologist trained in movement disorder or a specialist physician who has undergone training to administer botulinum toxin A to patients with movement disorders.
Funding status
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 2 September 2019.
Clostridium botulinum type A toxin-haemagglutinin complex (Dysport) 300 U and 500 U injection vials are recommended for inclusion on the MAF for the abovementioned indication from 1 November 2025.
MAF assistance does not apply to Botox 200 U injection vial or other brands of botulinum toxin A.
Botulinum toxin A for cervical dystonia (Updated 16 Sep 2025) [PDF, 147 KB]
PES Botulinum toxin A for treating cervical dystonia (Updated 16 Sep 2025) [PDF, 182 KB]